Bloggers

Lisa Banket
Cofounding Partner/Publisher
VIEW MY COMPLETE PROFILE
Taren Grom
Cofounding Partner/Editor-in-Chief
VIEW MY COMPLETE PROFILE
Heather Hummel
Project Coordinator
VIEW MY COMPLETE PROFILE
Dan Limbach
Producer, Webcast Network
VIEW MY COMPLETE PROFILE
Denise Myshko
Managing Editor
VIEW MY COMPLETE PROFILE
Kim Ribbink
Features Editor
VIEW MY COMPLETE PROFILE
Robin Robinson
Senior Editor
VIEW MY COMPLETE PROFILE
Marah Walsh
Cofounding Partner/New Business Development
VIEW MY COMPLETE PROFILE

PharmaVOICE Editors' Blog

Tuesday, January 14, 2014

Are You Ready for the Third Wave of Social Media for Business?


By Dan Limbach

The first wave of social media consisted of individuals experimenting with social media platforms and trying to understand it all. I considered this the infant stage. Most companies didn't even bother with it, letting the youth waste their time with it.

The second wave of social media involved placing social media specialists within companies, implementing dedicated teams to handle social media, and outside agencies specializing in social media on behalf of their clients. This was the adolescent stage. Smart companies started taking it seriously.

The third wave promises to expand social media usage in a big way. The medium has reached early adulthood. Everyone has a role to play. Will your company keep pace, or stay in perpetual catch-up mode?

Here is a compelling statement published in the Harvard Business Review in January, 2014.
In summary, the third wave of social business will move from enabling the few (i.e., the few marketers who manage corporate social media accounts) to mobilizing the many (i.e., the entire workforce and the “feet on the street”) to authentically engage at a personal and local level. After all, people buy from people, not companies.  People trust individuals, not corporations. It’s the way business has always been done, but now social business complements traditional methods and allows for companies and their employees to manage and measure this engagement at scale.
What does this mean? The days of people engaging with a brand will be replaced by people engaging with people associated with a brand. Instead of seeing tweets from @Pfizer, you can expect to see tweets from @PfizerJoeSmith.

Companies will need assistance more than ever in matters regarding social media strategy, messaging, design, and channel integration. The big difference is that employees will be the ones sending out the messages through their personal accounts rather than a small number if specialists managing impersonal brand accounts. Whether you are the Chief Marketing Officer or you work in the stockroom, you'll have an opportunity to have your voice heard through social media. In fact, your company will likely require your participation.

HBR Source:
http://blogs.hbr.org/2014/01/whats-the-endgame-for-social-media

Friday, January 3, 2014

Biobetters: Challenges and Opportunities - podcast

PRA podcast
Hazel Gorham, Ph.D.
Thought Leader: Hazel Gorham, Ph.D., Director, Biosimilars Development, PRA

The market of biologics is growing at a nearly twice the rate of pharma as a whole. Biobetters are the next big opportunity for biopharma to benefit from this growth. This podcast will explore the regulatory and scientific considerations for the development of biobetters.

Download Full Podcast

See All PharmaVOICE Podcasts

See All PharmaVOICE White Papers

podcast

How Working Together Effectively on a Clinical Trial is Like Doing a Successful Skydive - podcast

Barb Ruby
Barbara Ruby
Thought Leader: Barbara Ruby, Project Director, SynteractHCR, Inc.

In this episode, Ms. Ruby discusses how clinical trials are like skydiving, what some of the key challenges are in clinical trials, solving unexpected challenges, and creating a productive and collaborative relationship between CROs and sponsors.

Download Full Podcast

See All PharmaVOICE Podcasts

See All PharmaVOICE White Papers

podcast

Thursday, January 2, 2014

Risk-based monitoring (RBM): A shift in paradigm from the traditional experimental design - podcast

Theorem podcast
Mark Penniston and Alison Taber
Thought Leaders: Mark Penniston, Senior Vice President and General Manager, Clinical Analytics, Theorem Clinical Research and Alison Taber, Vice President of Global Data Management, Theorem Clinical Research

In this episode, Mr. Penniston and Ms. Taber talk about risk-based monitoring what it is, why it's important, what are the components, what skill sets or tools are necessary, and the challenges and opportunities related to risk-based monitoring.

Download Full Podcast

See All PharmaVOICE Podcasts

See All PharmaVOICE White Papers

podcast